The Singapore Israel Industrial R&D Foundation

Immunovative Therapies, Ltd

Immunovative Therapies, Ltd

Company: Immunovative Therapies, Ltd
Name: Michael Har-Noy
Designation: CEO/CTO
Country: Israel
Address: -
Tel: +972-50-9495963
Mobile: -
Fax: +972-4-9923536
Website: -
Technology Classification: Biopharmaceutical
Main Business Activity: Biopharmaceutical products

Company Profile, Products & Technologies, Target Market:

Immunovative Therapies, Ltd (ITL) is an early stage Israeli biopharmaceutical company specializing in the development of immunotherapy products for treatment of cancer and infectious disease where the active ingredients are living allogeneic immune cells. The Company has completed pre-clinical evaluation of an allogeneic cell product formulated with monoclonal antibody-conjugated biodegradable nanoparticles called AlloStim. AlloStim is designed to elicit the same curative anti-tumor effect that occurs in allogeneic bone marrow transplantation without the toxic and often lethal GVHD side-effect. AlloStim will be tested in Phase I/II clinical trials of Chronic Lymphocytic Leukemia (CLL) and in combination with cryoablation surgery in advanced prostate, colon and kidney cancers.

Brief description of proposed R&D project:

Pre-clinical results have demonstrated the strong adjuvant effect of AlloStim as a stimulator of innate immunity and its ability to mature dendritic cells to elicit Th1 immunity and break tolerance. These properties are thought to be beneficial in the design of a therapeutic vaccine for hepatitis C, which avoids the immune response by producing IL-10. We propose to work with a partner to develop a source of attenuated hepatitis C conjugated with chaparone proteins which will be formulated with AlloStim and administered to alloantigen-primed patients with hepatitis C infection as therapeutic vaccine.

Desired Profile of R&D Partner and its role in the proposed project:

We are seeking a partner with the facilities and expertise to develop a cell culture system to produce and purify attenuated hepatitis C virus and chaparone proteins. ITL will conduct phase I/II clinical trials of the proposed combination vaccine/AlloStim product at its clinical research center located in California USA.

R&D Partner Search

SIIRD promotes, facilitates and funds joint industrial R&D collaboration between Singapore-based companies and Israel-based companies.

R&D Partner Search Request Form

Please complete the 'R&D Partner Search Request Form' if your company is interested to search for technology partner in Singapore or Israel for joint R&D collaboration.

Our offices in Singapore and Israel will attempt to do a matching and make initial contact with any company which might be of interest to you.

The form will only be used for the purpose of matching potential R&D collaboration partners in Singapore and Israel under the SIIRD programme.

Companies who have been matched and who would like to jointly apply for funding for research and development  activities can do so by following the instructions in the  Proposal Submission page.

Alternatively, companies can refer to the lists of companies from Singapore and Israel who have indicated interest to look for R&D partners. Please contact the SIIRD Management if you have identified suitable partners from the lists and we will link you up with the relevant parties. Please refer to the hyperlinks above for access to the lists.

"The SIIRD program has enabled Kamedis to develop a unique product in cooperation with APN Singapore. We believe that the program has contributed the optimal framework for such cooperation and the SIIRD team has provided tremendous support at all stages of the process."
- Vered Caplan, CEO
Kamedis Ltd (Israel)